Jason Wolf

Scala Biodesign stands at the forefront of the current revolution in protein design. Scala’s no-code one-shot software enables R&D teams to design their proteins in a single design cycle, increasing success rates, reducing R&D effort, and accelerating time-to-market. Scalas technologies, developed by its founding team at the Weizmann Institute of Science, are backed by an unprecedented record of over 130 peer-reviewed publications and collaborations with 80 commercial and academic partners. This includes the first-ever one-shot design of a malaria vaccine candidate, now advancing through Phase II clinical trials, and proteins that were previously considered out of reach across biotherapeutics, enzymes for biomanufacturing, diagnostics, and other bio-based products. Utilizing this unique edge, Scala aims to disrupt the field and democratize the way proteins are developed. Scala has already partnered with five of the top-20 pharmaceutical companies and other market leaders across multiple verticals.

TREAT - Play to Impact

Quietly building whats next for defense.

Hoopo is recognized as a global leader in asset intelligence solutions, setting new standards with its state-of-the-art technology. Hoopo’s cutting-edge tracking solutions provide real-time visibility into your unpowered asset fleet, empowering businesses to optimize operations and enhance efficiency. With a portfolio of three unique trackers, Hoopo has the tracking solution to fit your operational needs. Learn more about our tracker at our website: www.hoopo.tech.

UltraSight aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. UltraSight’s AI-driven software provides real-time guidance and quality assessment to allow healthcare professionals, regardless of sonography proficiency, to consistently perform high-quality cardiac ultrasound in a variety of settings at the point of care, including clinics, community hospitals, ambulances, and remote and rural areas. UltraSight’s AI real-time guidance software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans. UltraSight’s software is an accessory to compatible general-purpose, diagnostic ultrasound systems. Full labeling is available at https://ultrasight.com/regulatory-approvals-and-labeling/. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices.

Repeat Sales Intelligence Platform for E-Commerce. At Bark-AI, we specialize in discovering which products, incentives, channels, and timing are most effective in converting first-time buyers into repeat customers. By connecting your E-commerce solution, analytics tools, and marketing automation platform, we empower you to analyze your performance, benchmark against your industry, forecast revenues, analyze discounts, and strategically plan your campaigns to enhance repeat sales.

illumex empowers enterprises to confidently deploy AI agents that deliver reliable, explainable, and compliant decisions at scale. Its Generative Semantic Fabric (GSF) platform transforms an enterprise’s organizational corpus of knowledge into AI-ready, business context embedded into semantic ontologies. These ontologies, which serve as a basis for data management, analytics, and agentic workflows, orchestrate AI agents to collaborate around shared context (via MCP) and interpret prompts with precision – eliminating hallucinations, ensuring compliance, and reducing TCO by up to 80%. Named a Gartner Cool Vendor in Agentic AI for Data Management and Tech Pioneer in AI Governance by World Economic Forum, illumex is setting the new standard for unified governed semantic data infrastructure in the age of agentic AI. illumex was founded by Inna Tokarev Sela, former Senior Director of Machine Learning at SAP, who brings two decades of experience leading large-scale initiatives to leverage data and AI.

Addionics is a growing, progressive startup based in Israel, the UK and the US. Addionics provides specialised improved rechargeable batteries by redesigning their architecture. With a novel and patent pending 3D metal fabrication method, we enhance performance, mileage, safety, cost and charging time of batteries. Addionics architecture work with current and emerging LIB technology. In short - we are betting on the race, not the horse. So whatever battery chemistry wins, our technology will enhance it yet further. There are two sides to the company - hardware making smart 3D current collectors, and software where AI will optimise given structures for given performance attributes.

Hyperspace is a high-performance hybrid (lexical and vector) information retrieval solution engineered to handle large-scale workloads with exceptional speed and efficiency. As a cloud-native database, it empowers developers, enterprises, and Gen AI applications to retrieve both structured and unstructured data, driving business value through improved customer satisfaction, optimized LLM models, and the full unlocking of Gen AI’s potential. By combining domain-specific computing with the power of specialized processors like GPUs and FPGAs for customizable tasks, Hyperspace achieves unparalleled efficiency. These processors use custom instructions optimized for specific tasks, therefore reducing the stack overhead and ensuring far greater performance and cost-effectiveness than general-purpose CPUs.

Nurami Medical, is an early commercial stage company revolutionizing next-generation surgical products for the repair, regeneration, and safe healing of soft tissues following internal surgeries, based on unique formulations of biomaterials and electrospun nanofiber-based bio-mimetic scaffolds. Our first product, ArtiFascia®, is an advanced, multi-layer, biomimetic dura repair patch, designed to improve Dura repair in neurosurgeries. ArtiFascia® is FDA-cleared (510K) for use in Dura repair. Terms of use of our media channels: https://www.nurami-medical.com/terms/

Scala Biodesign stands at the forefront of the current revolution in protein design. Scala’s no-code one-shot software enables R&D teams to design their proteins in a single design cycle, increasing success rates, reducing R&D effort, and accelerating time-to-market. Scalas technologies, developed by its founding team at the Weizmann Institute of Science, are backed by an unprecedented record of over 130 peer-reviewed publications and collaborations with 80 commercial and academic partners. This includes the first-ever one-shot design of a malaria vaccine candidate, now advancing through Phase II clinical trials, and proteins that were previously considered out of reach across biotherapeutics, enzymes for biomanufacturing, diagnostics, and other bio-based products. Utilizing this unique edge, Scala aims to disrupt the field and democratize the way proteins are developed. Scala has already partnered with five of the top-20 pharmaceutical companies and other market leaders across multiple verticals.

TREAT - Play to Impact

Quietly building whats next for defense.

Hoopo is recognized as a global leader in asset intelligence solutions, setting new standards with its state-of-the-art technology. Hoopo’s cutting-edge tracking solutions provide real-time visibility into your unpowered asset fleet, empowering businesses to optimize operations and enhance efficiency. With a portfolio of three unique trackers, Hoopo has the tracking solution to fit your operational needs. Learn more about our tracker at our website: www.hoopo.tech.

UltraSight aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. UltraSight’s AI-driven software provides real-time guidance and quality assessment to allow healthcare professionals, regardless of sonography proficiency, to consistently perform high-quality cardiac ultrasound in a variety of settings at the point of care, including clinics, community hospitals, ambulances, and remote and rural areas. UltraSight’s AI real-time guidance software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans. UltraSight’s software is an accessory to compatible general-purpose, diagnostic ultrasound systems. Full labeling is available at https://ultrasight.com/regulatory-approvals-and-labeling/. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices.